Miragen Therapeutics said this week that it has formed a sponsored research and licensing arrangement with the University of Colorado focused on microRNA therapeutics.
Under the sponsored-research portion of the deal, Miragen will fund the analysis of miRNA and gene-expression changes from a study of beta blocker effects on cardiac remodeling and gene expression conducted at the University of Colorado Cardiovascular Institute at the UC Denver School of Medicine.
The licensing deal will give the company the rights to commercialize intellectual property associated with the discoveries made during the project.
"Further analysis of the completed study, funded by Miragen, will provide the company with data on miRNA changes in human heart failure patients followed over two years with associated disease outcomes," Miragen said.
Specific financial terms of the deal were not disclosed.
"This [arrangement] provides us with the ability to analyze miRNA levels, as well as gene expression changes, in a given patient at specific points in time in their disease progression," Miragen President and CEO Bill Marshall said in a statement. "We believe this will provide a very powerful tool in stratifying our miRNA targets and support our mission of developing … miRNA-based therapeutics to treat patients with cardiovascular and muscle disease."